Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.

Fallowfield, L; Gagnon, D; Zagari, M; Cella, D; Bresnahan, B; Littlewood, T J; McNulty, P; Gorzegno, G; Freund, M

Fallowfield, L; Gagnon, D; Zagari, M; Cella, D; Bresnahan, B; Littlewood, T J; McNulty, P; Gorzegno, G; Freund, M.

Affiliation

Fallowfield L; Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. l.fallowfield@biols.susx.ac.uk

Br J Cancer ; 87(12): 1341-53, 2002 Dec 02.

Article in En | MEDLINE | ID: mdl-12454760

Subject(s)

Anemia/drug therapy; Antineoplastic Agents/therapeutic use; Erythropoietin/therapeutic use; Hematinics/therapeutic use; Quality of Life; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Anemia/chemically induced; Antineoplastic Agents/adverse effects; Double-Blind Method; Epoetin Alfa; Female; Hemoglobins/analysis; Humans; Male; Middle Aged; Neoplasms/drug therapy; Neoplasms/mortality; Recombinant Proteins; Survival Rate; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Erythropoietin / Hematinics / Anemia / Antineoplastic Agents Type of study: Clinical_trials Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2002 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google